{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:23:14Z","timestamp":1774459394323,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","pathologyjournal.rcpa.edu.au","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.pathol.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:57:32Z","timestamp":1614963452000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["CAR-T cell therapy: practical guide to routine laboratory monitoring"],"prefix":"10.1016","volume":"53","author":[{"given":"Adrian G.","family":"Selim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-2024","authenticated-orcid":false,"given":"Adrian","family":"Minson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.02.002_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.02.002_bib2","first-page":"40","article-title":"Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2021.02.002_bib4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.pathol.2021.02.002_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.pathol.2021.02.002_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.pathol.2021.02.002_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"10.1016\/j.pathol.2021.02.002_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2021.02.002_bib11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.02.002_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.02.002_bib13","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.02.002_bib14","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2021.02.002_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2021.02.002_bib17","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/blood-2018-99-120065","article-title":"Procalcitonin as a potential biomarker for differentiating bacterial infectious fevers from cytokine release syndrome","volume":"132","author":"Maakaron","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.pathol.2021.02.002_bib19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2021.02.002_bib20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/ajh.25518","article-title":"Chimeric antigen receptor T (CAR-T) cells present with reactive and pleomorphic morphology in bone marrow","volume":"94","author":"Han","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2021.02.002_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma","author":"Danylesko","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.pathol.2021.02.002_bib22","first-page":"1546","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.pathol.2021.02.002_bib23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.pathol.2021.02.002_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cyto.b.21591","article-title":"Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: a pitfall for minimal residual disease detection","volume":"94","author":"Xiao","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.pathol.2021.02.002_bib25","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2021.02.002_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2020.01770","article-title":"The chimeric antigen receptor detection toolkit","volume":"11","author":"Hu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2021.02.002_bib27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1538-7445.AM2019-1204","article-title":"Abstract 1204: design and development of anti-linker antibodies for the detection and characterization of CAR T cells","volume":"79","author":"Sievers","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2021.02.002_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cyto.b.21880","article-title":"New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry","volume":"98","author":"Maryamchik","year":"2020","journal-title":"C\u00a0Cytometry B Clin Cytom"},{"key":"10.1016\/j.pathol.2021.02.002_bib29","article-title":"Monitoring CAR T-cells using flow cytometry","author":"Demaret","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.pathol.2021.02.002_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.transproceed.2017.11.028","article-title":"Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T cells in peripheral blood","volume":"50","author":"Wang","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pathol.2021.02.002_bib31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.omtm.2020.02.003","article-title":"Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients","volume":"17","author":"Kunz","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pathol.2021.02.002_bib32","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.02.002_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2021.02.002_bib34","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2019-127094","article-title":"Peak lymphocyte count after CAR T infusion is a clinically accessible test that correlates with clinical response in axicabtagene ciloleucel therapy for lymphoma","volume":"134","author":"Novo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.02.002_bib35","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2021.02.002_bib36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2021.02.002_bib37","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2021.02.002_bib38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2021.02.002_bib39","first-page":"1","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","author":"Los-Arcos","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.pathol.2021.02.002_bib40","first-page":"509","article-title":"Measurement of circulating tumor DNA to guide management of patients with lymphoma","volume":"17","author":"Sriram","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.pathol.2021.02.002_bib41","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2019-132057","article-title":"Detectable circulating tumor DNA 28 Days after the CD19 CAR t-cell therapy, axicabtagene ciloleucel, is associated with poor outcomes in patients with diffuse large B-cell lymphoma","volume":"134","author":"Frank","year":"2019","journal-title":"Blood"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252100057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252100057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T06:06:15Z","timestamp":1671516375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130252100057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S003130252100057X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.02.002","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy: practical guide to routine laboratory monitoring","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}